New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For DVA;HUM;AGN;AET;EPOC;BAYRY;COV;MDT;BMY;CI;MCK;WLP;BDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
June 22, 2015
09:14 EDTCIOn The Fly: Pre-market Movers
Subscribe for More Information
09:02 EDTCICigna hits fresh highs after rejecting Anthem bid
Subscribe for More Information
09:02 EDTCIAnthem reiterates commitment to $184 per share proposal for Cigna
Subscribe for More Information
09:01 EDTCIAnthem reiterates commitment to $184 per share proposal for Cigna
Subscribe for More Information
08:52 EDTBMYPortola, Bristol-Myers, and Pfizer announce results from Phase 3 ANNEXA study
Subscribe for More Information
08:17 EDTMCKMcKesson appoints Kathy McElliogott as EVP, CIO, CTO
Subscribe for More Information
08:16 EDTHUM, CI, AETAnthem, Cigna deal would be negative for Catamaran, says Leerink
Subscribe for More Information
07:54 EDTAET, CI, HUMAnthem, Cigna deal likely to be consummated, says Leerink
Subscribe for More Information
07:16 EDTHUM, CI, AETAnthem should be bought after Cigna offer, says Stifel
After Anthem, (ANTM) offered to buy Cigna (CI) and the latter company rejected the bid, Stifel estimates that the deal would have been 10% accretive for Anthem in the first year and 20% accretive in the second year. The firm thinks that accretion from the deal will probably be higher than expected. It also recommends buying Aetna (AET) as it believes that the Anthem offer suggests that Aetna will benefit more than expected from its own deal. The firm is cautious on Humana (HUM), saying that it may lose two potential buyers in Anthem and Cigna, while Humana may retreat if Aetna does not acquire the company quickly.
06:51 EDTCI, HUM, AETHealth insurer tie-ups could cut competition, WSJ reports
Subscribe for More Information
06:37 EDTAET, HUM, CIHealth insurers may change policies based on King v. Burwell ruling, NYT says
Subscribe for More Information
06:03 EDTCICigna implied volatility of 37 at upper end of index
Subscribe for More Information
05:35 EDTBMYAllied-Bristol Life Sciences licenses IP from Harvard University
Allied-Bristol Life Sciences, a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb, announced that it has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Malcolm Whitman’s lab at the Harvard School of Dental Medicine. Building on previous studies conducted with Mark Sundrud, PhD, and Anjana Rao, PhD, at Boston Children’s Hospital, Professor Whitman’s lab, in collaboration with Professor Ralph Mazitschek, PhD, at the Center for Systems Biology at Massachusetts General Hospital, has shown that HF works through inhibition of Prolyl-tRNA synthetase, which leads to activation of an amino acid restriction response pathway. Based on this novel and differentiated mechanism, several lead molecules have been identified by the groups at HMS and MGH that have the potential to lead to effective therapy for several conditions including fibrotic and autoimmune diseases. The licensing agreement with Harvard’s Office of Technology Development is among the first in a series of discovery and development projects that Allied-Bristol Life Sciences intends to pursue. The license to the technology from Professor Whitman’s lab will be held by a new ABLS subsidiary specifically formed to pursue further research and pre-clinical development of the technology and associated molecules.
June 21, 2015
18:17 EDTCICigna calls Anthem offer 'inadequate,' 'woefully skewed'
Subscribe for More Information
16:57 EDTCICigna says Anthem proposal not in interest of shareholders, Bloomberg reports
Cigna (CI) has sent a letter of rejection to the Anthem (ANTM) board of directors, reports Bloomberg. Notably, Cigna acknowledged that the combination of the two companies has some potential benefits under the right circumstances. However, the company also remarked that Anthem has "complications" related to its Blue Cross and Blue Shield membership, and also cited antitrust actions as well as Anthem's "lagging" shares.
16:50 EDTCICigna board unanimously rejects Anthem proposal, DJ says
Subscribe for More Information
16:03 EDTCI, AET, HUMAetna makes offer to acquire Humana, WSJ says
Subscribe for More Information
15:26 EDTCIAnthem publicized offer for Cigna in order to pressure company, WSJ says
Subscribe for More Information
12:42 EDTMDTMedtronic reports five-year follow-up results for Endurant AAA stent graft
Subscribe for More Information
June 20, 2015
19:56 EDTCIAnthem proposes to acquire Cigna for $184 per share in cash, stock
Anthem (ANTM) announced that it has submitted a non-binding proposal to acquire Cigna (CI) for $184 per share in cash and stock. Under the terms of the proposal, which was delivered to Cigna’s board, Cigna stockholders would receive a total consideration that represents a value of $184 per share. The offer, which values the company at $53.8B on an enterprise basis, represents an “unaffected” premium to Cigna’s stockholders of more than 35.4%, based on the closing price of Cigna’s shares on May 28. The combined company would be an industry leader with greater than $115B in annual revenues, based on the most recent 2015 outlook publicly reported by both companies. Under the contemplated terms, the consideration would consist of approximately 31.4% Anthem shares and 68.6% cash and the combined company would reflect a pro forma equity ownership comprised of approximately 76.3% Anthem shareholders and approximately 23.7% Cigna stockholders. Anthem is also confident in its ability to complete any financing related to the acquisition, the company said. Anthem expects the combination would be accretive to operating earnings per share and that the combined enterprise would generate significant annual cost synergies by achieving operating and G&A efficiencies. Anthem expects to achieve adjusted earnings per share accretion of greater than 10% in year one, with the accretion more than doubling by year two following the closing of the transaction. Anthem is confident in the achievability of synergies and is committed to retaining investment grade debt ratings, the company noted. Anthem is confident in its ability to obtain regulatory approvals. In the course of previous negotiations, both companies have expressed a confidence that regulatory approval would not delay the consummation of the combination. This includes matters related to the Blue Cross Blue Shield Association. "Anthem has been engaged with Cigna to explore a potential combination since August 2014 and is making its proposal public today following Cigna’s refusal to reasonably negotiate and its insistence on securing governance matters that are not common practice in similar transactions. Anthem is confident in the value being offered, the growth potential of the combined company and its ability to successfully integrate the two organizations," the company stated.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use